Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Ramchandren · SciRah

Researcher profile · Semantic Scholar

R. Ramchandren

Share profile

R. Ramchandren — researcher profile on SciRah

h-index: 35
Works: 130
Citations: 7,822

Most-cited papers

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
P. Armand, A. Engert, A. Younes, M. Fanale +15 more
2018Journal of Clinical Oncology625 citations Open access
Semantic Scholar
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
M. Roemer, R. Redd, F. Cader, Christine J. Pak +25 more
2018Journal of Clinical Oncology326 citations Open access
Semantic Scholar
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
S. Ansell, J. Radford, J. Connors, M. Długosz-Danecka +17 more
2022New England Journal of Medicine274 citations Open access
Semantic Scholar
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
J. Connors, W. Jurczak, D. Straus, S. Ansell +25 more
2018New England Journal of Medicine273 citations Open access
Semantic Scholar
Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
J. Kuruvilla, R. Ramchandren, A. Santoro, E. Paszkiewicz-Kozik +18 more
2021The Lancet Oncology228 citations
Semantic Scholar
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma.
B. Pro, R. Advani, P. Brice, N. Bartlett +11 more
2017Blood221 citations Open access
Semantic Scholar
Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results
R. Advani, A. Moskowitz, N. Bartlett, J. Vose +13 more
2021Blood213 citations
Semantic Scholar
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
R. Ramchandren, E. Domingo-Domènech, A. Rueda, M. Trněný +16 more
2019Journal of Clinical Oncology212 citations Open access
Semantic Scholar
Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non-germinal center B-cell DLBCL.
A. Goy, R. Ramchandren, N. Ghosh, J. Muñoz +9 more
2019Blood131 citations Open access
Semantic Scholar
Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
D. Straus, M. Długosz-Danecka, J. Connors, S. Alekseev +23 more
2021The Lancet Haematology128 citations
Semantic Scholar
Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
O. O'Connor, M. Özcan, E. Jacobsen, J. M. Roncero +25 more
2019Journal of Clinical Oncology125 citations Open access
Semantic Scholar
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.
A. Forero-Torres, R. Ramchandren, A. Yacoub, M. Wertheim +13 more
2019Blood99 citations Open access
Semantic Scholar
Brentuximab vedotin with chemotherapy for Stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
D. Straus, M. Długosz-Danecka, S. Alekseev, Á. Illés +22 more
2019Blood94 citations Open access
Semantic Scholar
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
R. Merryman, L. Castagna, L. Giordano, V. Ho +62 more
2021Leukemia81 citations
Semantic Scholar
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
N. Dang, M. Ogura, S. Castaigné, L. Fayad +13 more
2017British Journal of Haematology64 citations Open access
Semantic Scholar
Cardiac Amyloid Detection by PET/CT Imaging of Iodine (124I) Evuzamitide (124I-p5+14): A Phase 1/2 Study.
J. Wall, E. Martin, Ronald H. Lands, R. Ramchandren +9 more
2023JACC Cardiovascular Imaging60 citations Open access
Semantic Scholar
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma
J. Timmerman, C. Herbaux, V. Ribrag, A. Zelenetz +16 more
2020American journal of hematology/oncology59 citations Open access
Semantic Scholar
Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment
Bai-Teng Zhao, Robert Chen, O. O'Connor, A. Gopal +6 more
2016British Journal of Clinical Pharmacology58 citations Open access
Semantic Scholar
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma
A. Herrera, A. Goy, A. Mehta, R. Ramchandren +7 more
2019American journal of hematology/oncology56 citations Open access
Semantic Scholar
Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma
P. Johnston, L. Pinter-Brown, G. Warsi, Kristen White +1 more
2018Experimental Hematology & Oncology53 citations Open access
Semantic Scholar
Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study
Michael L. Wang, R. Ramchandren, Robert W. Chen, Lionel Karlin +11 more
2021Journal of Hematology & Oncology46 citations Open access
Semantic Scholar
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma.
R. Merryman, R. Redd, T. Nishihori, J. Chavez +38 more
2021Blood Advances45 citations Open access
Semantic Scholar
Fimepinostat (CUDC‐907) in patients with relapsed/refractory diffuse large B cell and high‐grade B‐cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses
D. Landsburg, S. Barta, R. Ramchandren, C. Batlevi +15 more
2021British Journal of Haematology42 citations Open access
Semantic Scholar
Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial
A. Goy, Sevgi Kalayoğlu Beşışık, J. Drach, R. Ramchandren +9 more
2015British Journal of Haematology40 citations Open access
Semantic Scholar
Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma
T. Illidge, R. Bouabdallah, Robert Chen, A. Gopal +8 more
2015Leukemia and Lymphoma40 citations
Semantic Scholar
Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma
R. Ramchandren, R. Advani, S. Ansell, N. Bartlett +14 more
2019Clinical Cancer Research36 citations Open access
Semantic Scholar
Outcomes in patients with aggressive B‐cell non‐Hodgkin lymphoma after intensive frontline treatment failure
E. Ayers, Shao-Ying Li, L. Medeiros, D. Bond +36 more
2020Cancer31 citations Open access
Semantic Scholar
Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution
A. Sukari, M. Nagasaka, R. Alhasan, Dhaval Patel +8 more
2019Anticancer Research30 citations Open access
Semantic Scholar
KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).
J. Kuruvilla, R. Ramchandren, A. Santoro, E. Paszkiewicz-Kozik +16 more
2020Journal of Clinical Oncology29 citations
Semantic Scholar
Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study
R. Ramchandren, M. Fanale, A. Rueda, P. Armand +11 more
201727 citations
Semantic Scholar
First Multicenter, Randomized Phase 3 Study in Patients (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (LUMIERE trial; NCT01482962).
O. O'Connor, M. Ozcan, E. Jacobsen, Josep Vidal +17 more
2015Clinical advances in hematology & oncology : H&O27 citations
Semantic Scholar
Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
A. Herrera, N. Bartlett, R. Ramchandren, J. Vose +9 more
201625 citations
Semantic Scholar
Checkpoint blockade treatment sensitises relapsed/refractory non‐Hodgkin lymphoma to subsequent therapy
N. Carreau, P. Armand, R. Merryman, R. Advani +21 more
2020British Journal of Haematology23 citations Open access
Semantic Scholar
Brentuximab Vedotin and Nivolumab for Relapsed or Refractory Classic Hodgkin Lymphoma: Long-Term Follow-up Results from the Single-Arm Phase 1/2 Study
A. Moskowitz, R. Advani, N. Bartlett, J. Vose +13 more
2019Blood23 citations Open access
Semantic Scholar
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma
T. Witzig, P. Zinzani, T. Habermann, J. Tuscano +8 more
2017American journal of hematology/oncology22 citations Open access
Semantic Scholar
Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis
Mi-Na L. Xu, Ali M. Gabali, E. Hsi, Y. Fedoriw +7 more
2019American Journal of Surgical Pathology21 citations
Semantic Scholar
Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study
P. Armand, A. Engert, A. Younes, Hun Lee +14 more
2018Blood19 citations
Semantic Scholar
Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study
K. Patel, R. Ramchandren, M. Maris, A. Lesokhin +11 more
202018 citations Open access
Semantic Scholar
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
C. Ager, M. Reilley, C. Nicholas, Todd Bartkowiak +496 more
2016Journal for ImmunoTherapy of Cancer18 citations Open access
Semantic Scholar
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study
R. Ramchandren, P. Johnson, N. Ghosh, J. Ruan +17 more
2022EClinicalMedicine17 citations Open access
Semantic Scholar
Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma
P. Zinzani, R. Ramchandren, A. Santoro, E. Paszkiewicz-Kozik +14 more
2021Blood Advances17 citations Open access
Semantic Scholar
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma.
R. Merryman, N. Carreau, R. Advani, M. Spinner +29 more
2020The Oncologist15 citations Open access
Semantic Scholar
Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
B. Pro, R. Advani, P. Brice, N. Bartlett +10 more
201614 citations
Semantic Scholar
Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study
Jonathon B. Cohen, J. Kuruvilla, A. Engert, S. Ansell +14 more
2018Blood13 citations
Semantic Scholar
Seven-year overall survival analysis from ECHELON-1 study of A+AVD versus ABVD in patients with previously untreated stage III/IV classical Hodgkin lymphoma.
S. Ansell, D. Straus, J. M. Connors, W. Jurczak +16 more
2024Journal of Clinical Oncology11 citations Open access
Semantic Scholar
Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL)
R. Ramchandren, P. Johnson, N. Ghosh, J. Ruan +17 more
2019Blood11 citations Open access
Semantic Scholar
Pooled Safety Analysis and Efficacy of Tenalisib (RP6530), a PI3Kδ/γ Inhibitor, in Patients with Relapsed/Refractory Lymphoid Malignancies
S. Iyer, A. Huen, A. Ferreri, B. Haverkos +11 more
2018Blood11 citations
Semantic Scholar
First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1.
S. Ansell, J. Connors, J. Radford, W. Kim +16 more
2022Journal of Clinical Oncology10 citations
Semantic Scholar
Poor outcomes for double‐hit lymphoma patients treated with curative‐intent second‐line immunochemotherapy following failure of intensive front‐line immunochemotherapy
D. Landsburg, E. Ayers, D. Bond, K. Maddocks +13 more
2019British Journal of Haematology10 citations
Semantic Scholar
Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy
N. Carreau, O. Pail, P. Armand, R. Merryman +29 more
2018Blood10 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Advani×16
Invite
R. Advani — researcher profile on SciRah
P. Zinzani×13
Invite
P. Zinzani — researcher profile on SciRah
P. Armand×12
Invite
P. Armand — researcher profile on SciRah
K. Savage×12
Invite
K. Savage — researcher profile on SciRah

×12

Invite

S. Ansell — researcher profile on SciRah

N. Bartlett×11

Invite

N. Bartlett — researcher profile on SciRah

Jonathon B. Cohen×9

Invite

Jonathon B. Cohen — researcher profile on SciRah

Invite

K. Fenton — researcher profile on SciRah

Invite

T. Feldman — researcher profile on SciRah

Invite

A. Herrera — researcher profile on SciRah

Invite

A. Younes — researcher profile on SciRah

Invite

A. Santoro — researcher profile on SciRah